“Europe”, added Magrini, “on the approval of the Pfizer vaccine, has accelerated with great readiness for having done in a few hours what is done in weeks”. Even the president of the Agency, Giorgio Palù, said that “today” must be “celebrated as an exceptional day, like Vaccine day” scheduled for December 27th. “Never before have various vaccines been made as this time and today we already have one available that is 95% valid”. Aifa also underlined that the vaccine, in the coming months, will not be administered by appointment, but on call and that it can also be received during pregnancy or during the breastfeeding period.
Aifa has just given the green light to the Pfizer Biontech vaccine after Ema’s approval at European level. On December 27, in all Italian regions, the first vaccinations of healthcare personnel and the elderly of the RSA will begin. It’s still tough, but now we have an extra weapon. Power.
– Roberto Speranza (@robersperanza) December 22, 2020
“The second dose of the vaccine is given 3 weeks after the first and the immune response of the first dose is already visible from the sixth or seventh day. In the rare hypothesis that we become infected in this short period of time, it would probably be in a milder form “. In any case, active pharmacovigilance programs will be arranged with patient recall and text messages in the course of 2021 with analysis capacity at 3, 6 and 9 months to understand the immune response in the Italian population.
Vaccination against Covid-19 in Italy “will start on Sunday with a limited group of health workers. Then all health workers, about one million, will be vaccinated in January. So the people in the RSA, for a similar volume of population. Subsequently, the populations at risk, the elderly or individuals with specific pathologies “.
Aifa then denied the opposition to the development of monoclonal antibodies, “in the coming days we will certainly evaluate if there is an opportunity to carry out an experiment that is able to confirm the data already produced in the scientific literature”. Aifa, therefore, underlined the general manager, Nicola Magrini, on monoclonal antibodies “has always been open” and “the fact that it would have refused access to Italy is not true.”